Nigeria's renewed push to localize pharmaceutical production has drawn both praise and scrutiny, as the nation grapples with the gap between policy ambitions and tangible import substitution. The Presidential Initiative for Unlocking the Healthcare Value Chain (PVAC), launched in October 2023, seeks to elevate domestic manufacturing of healthcare products to 70% by 2030, aiming to mitigate reliance on imported medicines, active pharmaceutical ingredients (APIs), and medical equipment. However, recent trade data reveal a mixed picture, with pharmaceutical imports rebounding sharply in 2025 to $766.2 million—nearly matching pre-initiative levels—despite fiscal incentives and regulatory reforms introduced to stimulate local production.
The PVAC's strategy includes tax exemptions, cheaper financing, procurement guarantees, and streamlined regulatory approvals. These measures, however, have not yet translated into significant import reduction. According to UN Comtrade data compiled by the World Bank, Nigeria imported $767.4 million worth of pharmaceutical products in 2023, a figure that dipped to $653.5 million in 2024 before rising again to $766.2 million in 2025. This fluctuation underscores the challenge of transitioning from capacity-building to genuine import substitution, as the government acknowledges. 'If these incentives merely benefit producers without making medicines cheaper, better, or more available, the policy risks transferring advantages to manufacturers rather than the public,' a government official noted.
The initiative gained momentum after the exit of multinational firms like GlaxoSmithKline and Sanofi from direct operations in Nigeria, exposing vulnerabilities in the country's healthcare supply chain. In response, the government introduced an October 2024 Executive Order eliminating tariffs on pharmaceutical machinery and waiving duties on certain raw materials. Additional financing mechanisms, including a €50 million facility from the European Investment Bank and the Bank of Industry, have also been deployed. The proposed Medipool Programme, which promises long-term public procurement, is seen as a critical next step to ensure manufacturers can justify investments in production capacity.
Despite these efforts, the Federal Ministry of Health reports that local manufacturing now accounts for nearly half of healthcare products consumed in Nigeria. Registered pharmaceutical companies have grown from 180 in 2022 to over 200 by 2025, and plans for an API manufacturing plant signal progress. However, experts caution that the definition of 'healthcare products' is broader than pharmaceuticals, complicating direct comparisons with import data. 'A transparent yearly scorecard detailing local production of medicines, APIs, vaccines, and medical devices is essential to measure progress,' said a senior analyst.
The 2025 import rebound—17% higher than 2024—has intensified calls for accountability. 'Substitution must become visible in trade data if the PVAC is to succeed,' emphasized a policy researcher. While the initiative has laid groundwork through incentives and financing, the next phase hinges on expanding production and ensuring Nigerian-made medicines compete on price, quality, and scale. 'The real test is whether these interventions create globally competitive companies that reduce foreign-exchange exposure and lower medicine costs,' added a health economist.
Critics argue that without rigorous metrics, the PVAC risks becoming a cycle of temporary benefits rather than sustainable transformation. The government faces pressure to clarify how the 70% target translates into measurable outcomes, including specific benchmarks for APIs and medical devices. 'This is not a failure, but a program in progress,' a PVAC spokesperson stated. 'We are taking one step at a time, focusing on building capacity and ensuring public value.'
As Nigeria navigates this complex landscape, the success of its healthcare manufacturing drive will depend on transparency, measurable goals, and the ability to balance short-term incentives with long-term economic resilience. The coming years will determine whether the PVAC evolves from a policy experiment into a model for self-reliance in critical sectors.
Nigeria's Healthcare Manufacturing Drive Faces Import Substitution Challenges